1. Home
  2. CLNE vs LYEL Comparison

CLNE vs LYEL Comparison

Compare CLNE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clean Energy Fuels Corp.

CLNE

Clean Energy Fuels Corp.

HOLD

Current Price

$2.29

Market Cap

524.4M

Sector

Utilities

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.47

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLNE
LYEL
Founded
2001
2018
Country
United States
United States
Employees
N/A
161
Industry
Natural Gas Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
524.4M
556.1M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
CLNE
LYEL
Price
$2.29
$23.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$3.32
$30.60
AVG Volume (30 Days)
1.5M
74.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$341,599,000.00
$36,000.00
Revenue This Year
$1.13
N/A
Revenue Next Year
$22.65
$16,285.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$0.39
52 Week High
$3.11
$45.00

Technical Indicators

Market Signals
Indicator
CLNE
LYEL
Relative Strength Index (RSI) 45.88 55.08
Support Level $2.07 $21.27
Resistance Level $2.30 $27.30
Average True Range (ATR) 0.12 1.71
MACD -0.02 0.43
Stochastic Oscillator 15.00 74.68

Price Performance

Historical Comparison
CLNE
LYEL

About CLNE Clean Energy Fuels Corp.

Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: